CN102007207A - 一种浓缩培养液及其使用方法 - Google Patents
一种浓缩培养液及其使用方法 Download PDFInfo
- Publication number
- CN102007207A CN102007207A CN2008801287054A CN200880128705A CN102007207A CN 102007207 A CN102007207 A CN 102007207A CN 2008801287054 A CN2008801287054 A CN 2008801287054A CN 200880128705 A CN200880128705 A CN 200880128705A CN 102007207 A CN102007207 A CN 102007207A
- Authority
- CN
- China
- Prior art keywords
- cell
- concentrated culture
- culture fluids
- culture
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (11)
- 权 利 要 求1.一种用于大规模培养中国仓鼠卵巢细胞的浓缩培养液, 它由基础培养基和添加 物构成, 按浓縮培养液的总体积计, 所述的添加物由以下成分组成:维生素 c 10-25mg/L转铁蛋白 5-18mg/L乙醇胺 l-10mg/L亚硒酸盐 0.01-0.045 mg/L羟基丁酸钠 0.5-1.5mg/LA1C13«6H20 0.5-2.5mg/LAgN03 0.02-0.045mg/LCoCl3«6H20 0.05-0.3mg/LCuS04*5H20 0.002-0.004mg/LKBr 0.0005-0.0008mg/LFeS04*7H20 0.5-1.5mg/LNa2Si03 0.005-0.045mg/LLiCl 0.0005-0. OOlmg/LNiCl2»6H20 0.02-0.25 mg/LSnCl2«2H20 2.00-8. OOmg/LZnS04*7H20 0.5-2.5mg/L维生素 B6 0.01-0.2mg/L维生素 B12 0.01-0.5mg/L生物素 0.05-0.18mg/L叶酸 0.02-8. OOmg/L核黄素 0.1-0.15mg/L还原型谷胱甘肽 0.5-2.5mg/L腺嘌吟 5.5— 8.5 mg/L鸟嘌吟 5.5-8.5 mg/L尿嘧啶 5.5-8.5 mg/L胸腺嘧啶 0.25-1.5mg/L胞嘧啶 5.5— 8.5mg/L核糖 2.0-8.5mg/L脱氧核糖 2.0-8.5mg/LPrimatone 500- 3500mg/L
- 4-羟乙基哌嗪乙磺酸500- 3000mg/L(HEPES)β -巯基乙醇 0.2-2mg/L,其特征在于, 所述浓缩液中如下所示的成分的浓度为:1000— 9000mg/L 氯化钠 200-4000 mg/L 天冬氨酸200-9000 mg/L 天冬酰胺oo1 谷氨酸200-3 o000 mg/L 异亮氨酸300— 4500 mg/L 亮氨酸50-1000 mg/L 蛋氨酸100-2000 mg/L 苯丙氨酸500—10000 mg/L 丝氨酸50-1500 mg/L 苏氨酸25-1000 mg/L 色氨酸40-1000 mg/L 缬氨酸150-2000 mg/L 精氨酸0.01-0.5 mg/L 生物素2-100 mg/L 泛酸钙3-270 mg/L 氯化胆碱1-30 mg/L 叶酸5-900 mg/L 肌醇0.1-10 mg/L 烟酸胺0.01-1 mg/L 核黄素1-100 mg/L 硫胺素禾口 0.01_5 mg/L 维生素 B6。
- 2.如权利要求 1所述的浓缩培养液, 其特征在于, 所述浓缩液中如下所示的成分 的浓度为:1500- -6599 mg/L 氯化钠350- 2000 mg/L 天冬氨酸550— 5000 mg/L 天冬酰胺250- 3000 mg/L 谷氨酸500- 2500 mg/L 异亮氨酸500- 2500 mg/L 壳 ¾ @¾80- 700 mg/L 蛋氨酸200- 1250 mg/L 苯丙氨酸2000- -7000 mg/L 丝氨酸100- -700 mg/L 苏氨酸80- 350 mg/L 色氨酸80- 400 mg/L 缬氨酸300- 1200 mg/L 精氨酸0.05 - 0.2 mg/L 生物素10- -70 rag/L 泛酸钙10- 120 mg/L 氯化胆碱 2-15 mg/L 叶酸25-500 mg/L 肌醇0.5-5 rag/L 烟酸胺0.1-0.5 mg/L5-50 mg/L 硫胺素禾口 0.1_2 mg/L 维生素 B6。
- 3.—种如权利要求 1所述的浓缩培养液的制备方法, 它包括以下步骤: 将基础培 养基和添加物混合, 按浓缩培养液的总体积计, 所述的添加物由以下成分组成: 维生素 c 10-25mg/L转铁蛋白 5— 18mg/L乙醇胺 l-10mg/L亚硒酸盐 0.01-0.045 mg/L羟基丁酸钠 0.5—1.5mg/LA1C13«6H20 0.5-2.5mg/LAgN03 0.02-0.045mg/LCoCl3«6¾0 0.05-0.3mg/LCuS04*5H20 0.002-0.004mg/L0.0005-KBr0.0008mg/LFeS04*7H20 0.5-1.5mg/LNa2Si03 0.005-0.045mg/LLiCl 0.0005-0. OOlmg/LNiCl2«6H20 0.02-0.25 mg/LSnCL«2H20 2.00-8. OOmg/LZnS04*7H20 0.5-2.5mg/L维生素 B6 0.01-0.2mg/L维生素 B12 0.01-0.5mg/L生物素 0.05-0.18mg/L叶酸 0.02-8. OOmg/L核黄素 0.1-0.15mg/L还原型谷胱甘肽 0.5-2.5mg/L腺嘌吟 5.5-8.5 mg/L鸟嘌呤 5.5— 8.5 mgv'L尿嘧啶 5.5— 8.5 mg/L胸腺嘧啶 0.25-1.5mg/L胞嘧啶 5.5-8.5mg/L核糖 2.0-8.5mg/L脱氧核糖 2.0-8.5mg/LPrimatone 500-3500mg/L 4-羟乙基哌嗪乙磺o 500-3000mg/L酸 (HEPES)oβ-巯 1基乙醇 0.2-2mg/L,o其特征在于, 将如下所示的成分的浓度调整为:1000— 9000mg/ /L 氯化钠200-4000 mg/ 'L 天冬氨酸200-9000 mg/ 'L 天冬酰胺100-5000 mg/ 'L 谷氨酸200-3000 mg/ 'L 异亮氨酸300-4500 mg/ 'L 亮氨酸50-1000 mg/ L 蛋氨酸100-2000 mg/ 'L 苯丙氨酸500-10000 mg /L 丝氨酸50-1500 mg/ L 苏氨酸25—1000 mg/ L 色氨酸40—1000 mg/ L 缬氨酸150-2000 mg/ 'L 精氨酸'L 生物素2-100 mg/L 泛酸钙3-270 mg/L 氯化胆碱1-30 mg/L 叶酸5-900 mg/L 肌醇0.1-10 mg/L 烟酸胺0.01-1 mg/L 核黄素1-100 mg/L 硫胺素禾口 0.01_5 mg/ Ί 维生素 B6;优选地, 所述的基础培养基是 Dulbecco' s改良 Eagle' s培养基 (DMEM) 。
- 4.一种如权利要求 1所述的浓缩培养液的使用方法, 其特征在于, 所述的方法包 括步骤:在细胞接种 1一 5天后添加如权利要求 1所述的浓缩培养液, 添加的总剂量为 初始培养体积的 10— 100%; 所述的细胞是中国仓鼠卵巢细胞。
- 5.如权利要求 4所述的方法, 其特征在于, 所述的细胞接种密度为 2X10<sup>5</sup>/ml —2X 10<sup>6</sup>/ml。
- 6.如权利要求 4 所述的方法, 其特征在于, 所述的中国仓鼠卵巢细胞株选自 sTNFR融合基因中国仓鼠卵巢细胞、 表达 SCTLA4融合蛋白的中国仓鼠卵巢细胞、 或表达人源化抗 HER2单克隆抗体的中国仓鼠卵巢细胞。
- 7.如权利要求 4 所述的方法, 其特征在于, 添加的总剂量为初始培养体积的 15-60%
- 8.如权利要求 4所述的方法, 其特征在于, 每日添加浓缩培养液 1一 5次或每 1 - 5 日添加浓缩培养液 1次; 优选每日添加浓缩液 2— 4次或每 2— 4 日添加浓缩 培养液 1次。
- 9.如权利要求 4所述的方法, 其特征在于, 共添加浓缩培养液 5— 20天; 优 选共添加浓缩培养液 8— 16天。
- 10.如权利要求 4所述的方法,其特征在于,每次添加的浓缩培养液体积相同, 或在刚开始的 1一 5天添加所添加的浓缩培养液的重量的 15— 25 %, 中间 3— 9天 添加所添加的浓缩培养液的重量的 50— 70 %, 最后 1一 5天添加所添加的浓缩培养 液的重量的 15— 25 %。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2008/070750 WO2009127098A1 (zh) | 2008-04-18 | 2008-04-18 | 一种浓缩培养液及其使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102007207A true CN102007207A (zh) | 2011-04-06 |
CN102007207B CN102007207B (zh) | 2012-05-30 |
Family
ID=41198765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008801287054A Active CN102007207B (zh) | 2008-04-18 | 2008-04-18 | 一种浓缩培养液及其使用方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110111495A1 (zh) |
EP (1) | EP2345713A4 (zh) |
JP (1) | JP2011516086A (zh) |
CN (1) | CN102007207B (zh) |
BR (1) | BRPI0822597A2 (zh) |
CA (1) | CA2721585A1 (zh) |
WO (1) | WO2009127098A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105695416A (zh) * | 2016-03-21 | 2016-06-22 | 西藏诺迪康药业股份有限公司 | 一种哺乳动物细胞无血清培养基 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011134921A1 (en) * | 2010-04-26 | 2011-11-03 | Novartis Ag | Improved cell culture medium |
FR2997302B1 (fr) * | 2012-10-29 | 2015-02-06 | Assist Publ Hopitaux De Paris | Prevention et traitement des deficits en pyruvate deshydrogenase |
WO2015137640A1 (ko) * | 2014-03-13 | 2015-09-17 | 한양대학교 산학협력단 | 화학 조성 세포 배양 배지 첨가물 |
KR101714860B1 (ko) | 2014-03-13 | 2017-03-09 | 한양대학교 산학협력단 | 화학 조성 세포 배양 배지 첨가물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022545D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
DE4115722A1 (de) * | 1991-05-14 | 1992-11-19 | Boehringer Mannheim Gmbh | Serumfreies medium zur kultivierung von saeugerzellen |
AT409379B (de) | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
CN100537751C (zh) * | 2004-05-12 | 2009-09-09 | 华东理工大学 | 一种适合中国仓鼠卵巢细胞培养的无血清培养基 |
TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
WO2006047380A2 (en) * | 2004-10-22 | 2006-05-04 | Amgen, Inc. | Method and media for single cell serum-fee culture of cho cells |
CN101117624B (zh) * | 2006-03-15 | 2010-12-08 | 上海国健生物技术研究院 | 一种适合大规模中国仓鼠卵巢细胞培养的无血清培养基 |
-
2008
- 2008-04-18 EP EP08734108A patent/EP2345713A4/en not_active Withdrawn
- 2008-04-18 CA CA2721585A patent/CA2721585A1/en not_active Abandoned
- 2008-04-18 BR BRPI0822597A patent/BRPI0822597A2/pt not_active IP Right Cessation
- 2008-04-18 JP JP2011504299A patent/JP2011516086A/ja active Pending
- 2008-04-18 US US12/988,420 patent/US20110111495A1/en not_active Abandoned
- 2008-04-18 CN CN2008801287054A patent/CN102007207B/zh active Active
- 2008-04-18 WO PCT/CN2008/070750 patent/WO2009127098A1/zh active Application Filing
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105695416A (zh) * | 2016-03-21 | 2016-06-22 | 西藏诺迪康药业股份有限公司 | 一种哺乳动物细胞无血清培养基 |
CN105695416B (zh) * | 2016-03-21 | 2020-01-17 | 西藏诺迪康药业股份有限公司 | 一种哺乳动物细胞无血清培养基 |
Also Published As
Publication number | Publication date |
---|---|
EP2345713A1 (en) | 2011-07-20 |
CA2721585A1 (en) | 2009-10-22 |
JP2011516086A (ja) | 2011-05-26 |
EP2345713A4 (en) | 2012-07-11 |
US20110111495A1 (en) | 2011-05-12 |
BRPI0822597A2 (pt) | 2019-09-24 |
CN102007207B (zh) | 2012-05-30 |
WO2009127098A1 (zh) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7034991B2 (ja) | 改良型細胞培養培地 | |
CN100362098C (zh) | 适用于多种动物细胞大规模培养的无血清培养基 | |
CN102007207A (zh) | 一种浓缩培养液及其使用方法 | |
CN103773732B (zh) | 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺 | |
CN102827804A (zh) | 适用于Vero细胞微载体悬浮放大培养的培养基及方法 | |
CN101988047B (zh) | 一种低成本的昆虫细胞无血清培养基 | |
CA2769354A1 (en) | Method of producing a polypeptide or virus of interest in a continuous cell culture | |
CN104593316B (zh) | 昆虫细胞无血清培养基及其应用 | |
CN101974481A (zh) | 一种用于多种肾脏组织来源细胞生长的无血清培养基 | |
CA2795461A1 (en) | Improved cell cultivation process | |
CA2579643A1 (en) | Medium and culture of embryonic stem cells | |
CN104560882B (zh) | 一种降低酸性变体含量的cho细胞培养工艺 | |
CN101117624B (zh) | 一种适合大规模中国仓鼠卵巢细胞培养的无血清培养基 | |
CN107841482A (zh) | Mdck细胞无血清悬浮培养技术生产h9亚型流感疫苗 | |
JPH08508875A (ja) | 蛋白分泌細胞の流加回分培養法 | |
Okonkowski et al. | Cholesterol delivery to NS0 cells: challenges and solutions in disposable linear low-density polyethylene-based bioreactors | |
CN114045251B (zh) | 基因工程大肠杆菌高密度发酵培养基及其发酵工艺 | |
JP2859679B2 (ja) | 新規細胞株 | |
CN109053867A (zh) | 一种高密度发酵表达重组轮状病毒δvp8*抗原的培养方法 | |
CN101880703A (zh) | 一种流加癸酸盐发酵达托霉素的方法 | |
CN101250507A (zh) | 利用重组大肠杆菌高效生产丙酮酸氧化酶的分批式补料发酵工艺 | |
CN109628526B (zh) | 一种提高n-乙酰氨基葡萄糖产量的发酵方法 | |
CN107012115A (zh) | 支持细胞高密度悬浮培养的培养基及其制备方法 | |
WO1996030500A1 (en) | Culture medium for insect cells | |
CN104212768A (zh) | 用于培养微囊化重组中国仓鼠卵巢细胞的无蛋白培养基及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ANTIBODIES NATIONAL ENGINEERING RESEARCH CENTER Free format text: FORMER OWNER: SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD. Effective date: 20110422 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 NO. 399, LIBING ROAD, ZHANGJIANG HIGH-TECH. PARK, SHANGHAI, CHINA TO: 201203 BUILDING 3, NO. 399, LIBING ROAD, ZHANGJIANG HIGH-TECH. PARK, PUDONG NEW DISTRICT, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110422 Address after: Shanghai city 201203 libing road Zhangjiang High Tech Park of Pudong New Area No. 399 building 3 Applicant after: Antibodies National Engineering Research Center Address before: 201203 Chinese Shanghai Zhangjiang hi tech park, Bing Road No. 399 Applicant before: Shanghai CP Guojian Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160525 Address after: Bantian road in Longgang District of Shenzhen city streets Graceland 518000 Guangdong province No. 14 Patentee after: ShenZhen Sciprogen Bio-pharmaceutical Co., Ltd. Address before: Shanghai city 201203 libing road Zhangjiang High Tech Park of Pudong New Area No. 399 building 3 Patentee before: Antibodies National Engineering Research Center |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180815 Address after: 201203 Pudong New Area 3 free trade trial area, 399 Li Bing Road, Shanghai Patentee after: Antibodies National Engineering Research Center Address before: 518000 No. 14, Ya Yuan Road, Bantian street, Longgang District, Shenzhen, Guangdong. Patentee before: ShenZhen Sciprogen Bio-pharmaceutical Co., Ltd. |